Adicet Bio Stock Is Falling Premarket - Here's Why

Adicet Bio Inc ACET shared safety and efficacy data from its Phase 1 study of ADI-001 for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma (NHL)JMP Securities downgraded Adicet Bio to Market Perform from Market Outperform rating.

The Phase 1 trial included patients who had undergone a median of 4 lines of prior therapy, with 50% having previously progressed on autologous CAR T therapy.

Also Read: Adicet Bio's Cancer Candidate Shows Anti-Tumor Activity In Preclinical Study.

ADI-001 demonstrated a 71% overall response rate (ORR) and 63% complete response (CR) rate across all dose levels.

83% ORR and 67% CR rate were observed in heavily pre-treated patients who had progressed on prior CAR T.

A 6-month CR rate of 25%, and in patients who had progressed following autologous CD19 CAR T therapy, the CR rate was 67% with a 6-month CR rate of 33%.

The company plans to progress the ADI-001 program into a potential pivotal Phase 2 study in post-CAR T large B-cell lymphoma (LBCL) in the first half of 2024.

In addition, an update on efficacy, 6-month CR rate, and safety data from additional post-CAR T LBCL patients is expected in the second half of 2024.

According to Chen Schor, President and CEO of Adicet Bio, the autologous CD19 CAR T market is growing rapidly, exceeding an annual run rate of $2.2 billion.

Despite this, around 60-70% of patients progress, indicating a significant unmet medical need.

Adicet selected the recommended Phase 2 dose (RP2D) as 1 billion CAR-positive cells (dose level 4).

ADI-001 was generally well-tolerated with no dose-limiting toxicities or graft vs. host disease occurrences.

No significant incidences of CRS (cytokine release syndrome) or ICANS (immune effector cell associated neurotoxicity syndrome) were observed.

Price Action: ACET shares are down 10.50% at $4.17 during the premarket session on the last check Tuesday.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CarePre-Market OutlookMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!